NTRK inhibitors, such as larotrectinib, may be used after at least one prior line of therapy for those patients who harbour NTRK fusions, which is more commonly seen in MSI-H tumours without RAS or BRAF mutations [27]. This evidence concerns the gene BRAF and neoplasm.